<DOC>
	<DOCNO>NCT00179764</DOCNO>
	<brief_summary>The purpose research study evaluate effectiveness transplantation high dose peripheral blood stem cell ( stem cell special cell find blood bone marrow produce new blood cell ) treatment non-myeloablative chemotherapy ( toxic bone marrow ) . In addition , study assess side effect transplant .</brief_summary>
	<brief_title>Immunoablative Mini Transplant ( Hematopoietic Peripheral Blood Stem Cell Transplant HPBSC )</brief_title>
	<detailed_description>The standard treatment many disorder bone marrow high dose chemotherapy whole-body radiation treatment follow stem cell transplant . This type transplant suppress kill immune system , toxic bone marrow . This study use chemotherapy regimen suppress patient 's immune system ; however , non-myeloablative ( toxic bone marrow ) . It use whole-body radiation treatment . This approach minimize short- long-term effect transplantation . Other study show use chemotherapy follow bone marrow transplantation without whole-body radiation produce similar result treatment whole-body radiation . Patients give chemotherapy Fludarabine Busulfan prior stem cell transplant . This treatment destroy diseased cell , also kill normal bone marrow cell . Following experimental treatment , patient give stem cell central venous catheter ( tube insert vein ) . When healthy stem cell give patient , replace destroy bone marrow cell produce new blood cell . The Allogeneic ( one 's ) stem cell use experimental transplant obtain relate matched donor unrelated match donor locate National Marrow Donor Program .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients recurrent solid tumor Patients malignant melanoma Patients hematological malignancy . Chronic myelogenous leukemia chronic accelerate phase , include chronic myelomonocytic leukemia ( juvenile chronic myelogenous leukemia ( JCML ) CMML ) . Acute lymphoblastic leukemia ( ALL ) First remission highrisk ALL ( Ph+ initial high white blood cell ( WBC ) ( 411 ) infant less 1 year CALLA negative ) Second subsequent remission ALL isolate extramedullary disease therapy . Acute nonlymphocytic leukemia ( ANLL ) Patients ANLL first remission match sibling donor . ANLL second remission , patient achieve initial partial remission &lt; 15 % blast , early relapse . Myelodysplastic syndrome ( MDS ) : refractory anemia ( RA ) , refractory anemia excess blast ( RAEB ) , refractory anemia excess blast transformation ( RAEBT ) CMML/JCML . Selected immunodeficiency : WiskottAldrich syndrome . Severe combine immunodeficiency variant require ablation . HyperImmunoglobulin M ( IgM ) syndrome . Other immune deficiency approval medical director . Bone marrow failure syndrome ( single multiple hematopoietic line ) Venous access : A double lumen central vascular access device equivalent require patient enter protocol . Informed consent : The donor patient and/or patient 's legally authorized guardian must acknowledge write consent become study subject obtain accordance institutional policy approve United States ( U.S. ) Department Health Human Services . Patient organ function requirement : Adequate renal function : serum creatinine &lt; 2 x normal , creatinine clearance calculate Schwartz formula , glomerular filtration rate ( GFR ) &gt; 40 ml/min/1.73m2 , equivalent GFR determine institutional normal range . Adequate liver function : total bilirubin &lt; /= 2 x normal ; Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) &lt; /= 4 x normal . Adequate cardiac function : shortening fraction &gt; 24 % echocardiogram , ejection fraction &gt; 30 % radionuclide angiogram . Adequate pulmonary function : Diffusion Lung Capacity Carbon Monoxide ( DLCO ) , Forced Expiratory Volume 1 second ( FEV1 ) / Forced Vital Capacity ( FVC ) &gt; 30 % pulmonary function test . For child uncooperative pulmonary function test evidence dyspnea rest exercise intolerance , pulse oximetry &gt; 94 % room air consider acceptable . Performance status : Lansky Score &gt; /= 60 % child &lt; /= 16 year age ; Karnofsky &gt; 60 % status &gt; 16 year age . Patients pregnant Inability find suitable donor patient Patient HIVpositive Patient active Hepatitis B Disease progression relapse prior HPC infusion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Patients recurrent solid tumor</keyword>
	<keyword>Patients malignant melanoma</keyword>
	<keyword>Patients hematological malignancy</keyword>
	<keyword>Acute lymphoblastic leukemia ( ALL )</keyword>
	<keyword>Acute myelogenous leukemia ( AML )</keyword>
</DOC>